Products Cetrorelix is commercially available as a powder and solvent for the preparation of a solution for injection (Cetrotide). It has been approved in many countries since 2003. Structure and properties Cetrorelix acetate is present in drugs as cetrorelix acetate. It is a decapeptide and a derivative of gonadotropin-releasing hormone (GnRH) produced by the hypothalamus, … Cetrorelix
Products GnRH analogs are commercially available in many countries in the form of injectables, implants, and nasal sprays, among others. The first agent to be approved was goserelin (Zoladex) in 1990. Structure and properties GnRH analogs are synthetically produced derivatives of gonadotropin-releasing hormone (GnRH, LHRH) produced in the hypothalamus. GnRH is a decapeptide and has … GnRH Analogs
Effects GnRH antagonists are competitive antagonists of GnRH at pituitary receptors, inhibiting the release of LH and FSH. Indications Suppression of premature LH peaks and prevention of premature ovulation in women undergoing assisted reproductive medicine. Prostate cancer in adult men (degarelix). Agents Cetrorelix (Cetrotide) Degarelix (Firmagon) Ganirelix (Orgalutran, out of trade)
Products Ganirelix was commercially available as a solution for injection in prefilled syringes (Orgalutran). It was approved in many countries since 2000. It was discontinued in 2019. Structure and properties Ganirelix is a decapeptide and a derivative of gonadotropin-releasing hormone (GnRH) produced by the hypothalamus. It differs from the natural hormone at positions 1, 2, … Ganirelix
Products Degarelix is commercially available as a powder and solvent for solution for injection (Firmagon). It was approved in many countries in February 2010. Structure and properties Degarelix is a decapeptide derived from gonadotropin-releasing hormone (GnRH), a hormone of the hypothalamus. It is present in drugs as degarelix acetate and differs from the natural substance … Degarelix
